Compare FSP & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSP | CALC |
|---|---|---|
| Founded | 1981 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.6M | 88.3M |
| IPO Year | N/A | N/A |
| Metric | FSP | CALC |
|---|---|---|
| Price | $0.79 | $0.61 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 349.4K | ★ 2.8M |
| Earning Date | 02-11-2026 | 11-12-2025 |
| Dividend Yield | ★ 4.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,497,000.00 | N/A |
| Revenue This Year | $4.36 | N/A |
| Revenue Next Year | $0.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.82 | $0.59 |
| 52 Week High | $2.09 | $7.20 |
| Indicator | FSP | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 29.75 | 17.64 |
| Support Level | $0.82 | $0.59 |
| Resistance Level | $0.92 | $5.95 |
| Average True Range (ATR) | 0.04 | 0.41 |
| MACD | -0.01 | -0.60 |
| Stochastic Oscillator | 4.17 | 0.57 |
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.